Ionis Pharmaceuticals Inc.


Stock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Reports Positive Data from Phase 2 Study in Patients with Type 2 Diabetes

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes.  In this …

Chardan Bullish on AveXis Inc (AVXS) Following Rival Spinraza Broad-Label Approval

Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light of competitors Biogen Inc (NASDAQ:BIIB) and Ionis Pharmaceuticals …

Leerink Swann Boosts Price Target on Ionis Pharmaceuticals Inc (IONS); Here’s Why

Following the news that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has secured FDA approval in a major way for its pipeline drug Spinraza in the indication …

Stock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Earns Milestone Payment from Janssen for Advancing a New Program Under GI Collaboration

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced today that it has earned $5 million milestone payment from Janssen Biotech, Inc. (Janssen) associated with the validation …

Company Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced today that it has advanced its lead drug candidate IONIS-AZ4-2.5-LRx, which has now been renamed AZD8233, into preclinical …

Company Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc and Akcea Announce Positive Results from Compass Phase 3 Study of Volanesorsen

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and its wholly-owned subsidiary Akcea Therapeutics announced that the Phase 3 COMPASS study met its primary endpoint.  COMPASS is …

Stock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced today that it has earned $28 million from AstraZeneca (NYSE:AZN) following AstraZeneca’s completion of IND-supporting studies and license …

Piper Jaffray Sings the Praises of Ionis Pharmaceuticals Inc (IONS) as a Top Mid-Cap Pick Following Management Meetings

Last week, Piper Jaffray analyst Joshua Schimmer hosted Richard Geary, Senior Vice President (SVP) of Ionis Pharmaceuticals Inc (NASDAQ:IONS), as well as Wade …

Cowen Cautiously Optimistic on Ionis Pharmaceuticals Inc (IONS) as it Circles Approval in SMA

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its third-quarter report today as well as offered a clinical update. In reaction, Cowen analyst Eric Schmidt notes …

Company Update (NASDAQ:IONS): Here’s Why Ionis Pharmaceuticals Inc Shares Rose 11% Today

Ionis Pharmaceuticals Inc (NASDAQ:IONS) should be smiling after the company, along with Biogen (NASDAQ:BIIB), announced that SPINRAZATM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts